Artelo presents favorable human metabolite profile for non-opioid pain candidate

Artelo Biosciences (NASDAQ:ARTL) announced encouraging human metabolite identification and profiling data for its lead drug candidate, ART26.12, as the biotechnology company aims to de-risk the development of its novel non-opioid pain therapy.

The data, presented by Lead Medicinal Chemist Myles Osborn at the 7th RSC-BMCS/DMDG New Perspectives in DMPK and Medicinal Chemistry Conference in London, isolates plasma samples taken from healthy volunteers during the company's recently wrapped Single Ascending Dose (SAD) study.

Early characterization of absorption, distribution, metabolism, and excretion (ADME) profiles is critical in clinical trials, as pharmacokinetic complications have historically accounted for up to 40% of all experimental drug failures.

The primary findings indicate that Artelo's candidate carries a low-risk metabolic footprint.

Following a single 900 mg oral dose of ART26.12, researchers detected only three distinct metabolites circulating within the human plasma.

Crucially, the total accumulation of these metabolites comprised just 7% of overall drug exposure, meaning the vast majority of the circulating substance remained intact as the parent compound.

The most prominent metabolite accounted for roughly 5% of overall drug exposure and demonstrated biological potency comparable to ART26.12 itself.

Furthermore, all three discovered human metabolites matched those previously evaluated during preclinical animal toxicology modeling, clearing them of any safety or toxicity concerns.

Management notes that the absence of human-specific metabolites or complex metabolic burdens should significantly lower corporate capital costs and reduce regulatory timelines moving forward.